Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination Therapies Targeting HDAC and IKK in Solid Tumors
Ivana Vancurova, Mohammad M. Uddin, Yue Zou, et al.
Trends in Pharmacological Sciences (2017) Vol. 39, Iss. 3, pp. 295-306
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Amit Kumar Singh, Anupam Bishayee, Abhay K. Pandey
Nutrients (2018) Vol. 10, Iss. 6, pp. 731-731
Open Access | Times Cited: 191
Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer
Priyanga Selvakumar, Aja Badgeley, Paige Murphy, et al.
Nutrients (2020) Vol. 12, Iss. 3, pp. 761-761
Open Access | Times Cited: 160
Harnessing anti‐tumor and tumor‐tropism functions of macrophages via nanotechnology for tumor immunotherapy
Yanhui Zheng, Yaobao Han, Qiao Sun, et al.
Exploration (2022) Vol. 2, Iss. 3
Open Access | Times Cited: 116
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 48
Advances in targeting histone deacetylase for treatment of solid tumors
Mu-Qi Shi, Ying Xu, Xin Fu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 23
Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases
Himavanth Gatla, Nethaji Muniraj, Prashanth Thevkar, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 5, pp. 1110-1110
Open Access | Times Cited: 81
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 66
The emerging roles of HDACs and their therapeutic implications in cancer
Rihan Hai, Deyi Yang, Feifei Zheng, et al.
European Journal of Pharmacology (2022) Vol. 931, pp. 175216-175216
Closed Access | Times Cited: 48
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 21
Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma
Hong Ren, Zhenkai Wu, Jia Tan, et al.
Advanced Science (2024) Vol. 11, Iss. 31
Open Access | Times Cited: 6
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells
Yue Zou, Mohammad M. Uddin, Sveta Padmanabhan, et al.
Journal of Biological Chemistry (2018) Vol. 293, Iss. 40, pp. 15483-15496
Open Access | Times Cited: 48
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
Nicole Kiweler, Desirée Wünsch, Matthias Wirth, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 146, Iss. 2, pp. 343-356
Open Access | Times Cited: 44
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3–Specific CAR T Cells in Solid Tumors
Xinyuan Lei, Zhanpeng Ou, Zhao‐hui Yang, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 13, pp. 3757-3771
Open Access | Times Cited: 40
CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma
Yueshuo Li, Chenxing Yang, Longlong Xie, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Targeting Wnt signaling for improved glioma immunotherapy
Margarita Gutova, Jonathan Hibbard, Eric Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Maria Mrakovcic, Lauren Bohner, Marcel Hanisch, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 12, pp. 3952-3952
Open Access | Times Cited: 43
A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo
Yin-Ru Li, Fangfang Liu, Wenbo Liu, et al.
Biochemical Pharmacology (2022) Vol. 201, pp. 115070-115070
Closed Access | Times Cited: 19
Histone deacetylase 6’s function in viral infection, innate immunity, and disease: latest advances
Min Qu, Huijun Zhang, Pengyuan Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
Levi W. Evans, Bradley S. Ferguson
Nutrients (2018) Vol. 10, Iss. 8, pp. 1120-1120
Open Access | Times Cited: 35
Epigenetic inhibition assisted chemotherapeutic treatment of lung cancer based on artificial exosomes
Yinshan Lin, Songpei Li, Zekuan Xiao, et al.
Pharmacological Research (2021) Vol. 171, pp. 105787-105787
Closed Access | Times Cited: 25
IKKβ activation promotes amphisome formation and extracellular vesicle secretion in tumor cells
Xueqiang Peng, Liang Yang, Yingbo Ma, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2020) Vol. 1868, Iss. 1, pp. 118857-118857
Open Access | Times Cited: 25
Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis
Fengyan Jin, Jian Li, Jianfeng Guo, et al.
European Heart Journal Open (2021) Vol. 1, Iss. 2
Open Access | Times Cited: 22
Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Sheng Wang, Dexi Zhou, Zhenyu Xu, et al.
Current Drug Targets (2019) Vol. 20, Iss. 11, pp. 1180-1202
Closed Access | Times Cited: 23
CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells
Zhaojun Li, Ya‐Jun Hou, Gangping Hao, et al.
Journal of Cell Communication and Signaling (2020) Vol. 14, Iss. 4, pp. 377-387
Open Access | Times Cited: 21
Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity
Angelico D. Aputen, Maria George Elias, Jayne Gilbert, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2181-2181
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top